Orforglipron
ATTAIN-OA PAIN
Eli Lilly · Phase 3 · Active, not recruiting · Enrollment 800
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Orforglipron (GZT1) | n/r | n/r | n/r | n/r |
| Placebo (GZT1) | n/r | n/r | n/r | n/r |
| Orforglipron (GZT2) | n/r | n/r | n/r | n/r |
| Placebo (GZT2) | n/r | n/r | n/r | n/r |
Not shown
- Orforglipron (GZT1): endpoint not reported
- Placebo (GZT1): endpoint not reported
- Orforglipron (GZT2): endpoint not reported
- Placebo (GZT2): endpoint not reported